309 related articles for article (PubMed ID: 34605222)
1. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
Chen P; Zhang X; Ding R; Yang L; Lyu X; Zeng J; Lei JH; Wang L; Bi J; Shao N; Shu D; Wu B; Wu J; Yang Z; Wang H; Wang B; Xiong K; Lu Y; Fu S; Choi TK; Lon NW; Zhang A; Tang D; Quan Y; Meng Y; Miao K; Sun H; Zhao M; Bao J; Zhang L; Xu X; Shi Y; Lin Y; Deng C
Adv Sci (Weinh); 2021 Nov; 8(22):e2101176. PubMed ID: 34605222
[TBL] [Abstract][Full Text] [Related]
2. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
[TBL] [Abstract][Full Text] [Related]
3. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.
Lin YY; Gao HF; Li H; Hu Q; Du BL; Li S; Xu FP; Cheng MY; Zou JC; Zheng XX; Zhu T; Wang K
Int J Cancer; 2024 Aug; 155(4):697-709. PubMed ID: 38577882
[TBL] [Abstract][Full Text] [Related]
5. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N
Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484
[TBL] [Abstract][Full Text] [Related]
7. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
8. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer.
He X; Jiang Y; Zhang L; Li Y; Hu X; Hua G; Cai S; Mo S; Peng J
Front Bioeng Biotechnol; 2023; 11():1190637. PubMed ID: 37284236
[No Abstract] [Full Text] [Related]
11. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
13. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
[TBL] [Abstract][Full Text] [Related]
14. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY; Kim SM; Lim S; Lee JY; Choi SJ; Yang SD; Yun MR; Kim CG; Gu SR; Park C; Park AY; Lim SM; Heo SG; Kim H; Cho BC
Clin Cancer Res; 2021 Aug; 27(15):4397-4409. PubMed ID: 34083237
[TBL] [Abstract][Full Text] [Related]
15. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy.
Shu D; Shen M; Li K; Han X; Li H; Tan Z; Wang Y; Peng Y; Tang Z; Qu C; Jin A; Liu S
Ann Med; 2022 Dec; 54(1):2581-2597. PubMed ID: 36194178
[TBL] [Abstract][Full Text] [Related]
16. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development.
Xiang D; He A; Zhou R; Wang Y; Xiao X; Gong T; Kang W; Lin X; Wang X; ; Liu L; Chen YG; Gao S; Liu Y
Theranostics; 2024; 14(8):3300-3316. PubMed ID: 38855182
[TBL] [Abstract][Full Text] [Related]
17. Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics.
Bhatia S; Kramer M; Russo S; Naik P; Arun G; Brophy K; Andrews P; Fan C; Perou CM; Preall J; Ha T; Plenker D; Tuveson DA; Rishi A; Wilkinson JE; McCombie WR; Kostroff K; Spector DL
Cancer Res; 2022 Apr; 82(7):1174-1192. PubMed ID: 35180770
[TBL] [Abstract][Full Text] [Related]
18. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.
Geevimaan K; Guo JY; Shen CN; Jiang JK; Fann CSJ; Hwang MJ; Shui JW; Lin HT; Wang MJ; Shih HC; Li AF; Chang SC; Yang SH; Chen JY
Front Oncol; 2022; 12():883437. PubMed ID: 35719949
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer.
Karakasheva TA; Gabre JT; Sachdeva UM; Cruz-Acuña R; Lin EW; DeMarshall M; Falk GW; Ginsberg GG; Yang Z; Kim MM; Diffenderfer ES; Pitarresi JR; Li J; Muir AB; Hamilton KE; Nakagawa H; Bass AJ; Rustgi AK
Sci Rep; 2021 Oct; 11(1):21304. PubMed ID: 34716381
[TBL] [Abstract][Full Text] [Related]
20. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
